
Novavax Inc (NASDAQ:NVAX) shares are trading higher Thursday after the company announced that its COVID-19 vaccine was recommended for an expanded conditional marketing authorization in the European Union for adolescents aged 12 through 17.
The European Medicines Agency committee based its recommendation of Nuvaxovid on results from the Phase 3 PREVENT-19 clinical trial. Nuvaxoid is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.